1. Home
  2. LMRI vs COLL Comparison

LMRI vs COLL Comparison

Compare LMRI & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LMRI

Lumexa Imaging Holdings Inc. Common Stock

N/A

Current Price

$17.50

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$46.21

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMRI
COLL
Founded
2018
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
LMRI
COLL
Price
$17.50
$46.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$22.67
$47.50
AVG Volume (30 Days)
1.0M
483.2K
Earning Date
01-01-0001
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.63
Revenue
$1,003,375,000.00
$757,067,000.00
Revenue This Year
N/A
$26.35
Revenue Next Year
N/A
$3.67
P/E Ratio
N/A
$28.10
Revenue Growth
1.38
26.34
52 Week Low
$15.81
$23.23
52 Week High
$19.45
$50.79

Technical Indicators

Market Signals
Indicator
LMRI
COLL
Relative Strength Index (RSI) N/A 46.54
Support Level N/A $44.51
Resistance Level N/A $50.79
Average True Range (ATR) 0.00 1.36
MACD 0.00 -0.66
Stochastic Oscillator 0.00 29.95

Price Performance

Historical Comparison
LMRI
COLL

About LMRI Lumexa Imaging Holdings Inc. Common Stock

Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities including MRIs, CT scans, PET scans, X-rays, ultrasounds, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated from the Outpatient segment, which generates revenue by performing imaging studies and providing radiologists' interpretations of those studies.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: